Skip to content
Pharma Observatory a Scientist.com platform

Condition (MeSH)

Ocular Hypertension

ClinicalTrials.gov lists 2,146 trials for Ocular Hypertension or a narrower condition beneath it. Alcon Research has the most among industry and government lead sponsors, with 135.

MeSH D009798 Eye Diseases C11
Email me this page as a PDF

Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Phase 1 Phase 1 83 Phase 1/2 Phase 1/2 47 Phase 2 Phase 2 162 Phase 2/3 Phase 2/3 19 Phase 3 Phase 3 228 Phase 4 Phase 4 280 Not applicable Not applicable 774 Observational Observational 550 Phase 1 Phase 1 83 Phase 1/2 Phase 1/2 47 Phase 2 Phase 2 162 Phase 2/3 Phase 2/3 19 Phase 3 Phase 3 228 Phase 4 Phase 4 280 Not applicable Not applicable 774 Observational Observational 550

Trials per phase (log scale)

2 more sections with rows

654 of the 2,146 trials are tagged with Ocular Hypertension itself; the rest are tagged with a narrower condition beneath it.

Get the Ocular Hypertension report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

When did Ocular Hypertension trials start? (35)

Shown in this order: most recent first, 1990 onwards. 2026 is partial: trials registered with a 2026 start date so far, not a full year. 3 trials are registered to start in 2027 or later, and not listed here.

Trials over time, by phase

  • Phase 1
  • Phase 1/2
  • Phase 2
  • Phase 2/3
  • Phase 3
  • Phase 4
  • Not applicable
  • Observational
  • Other (Unknown)

Top of scale: 126

1992: 3 trials (Phase 3 3) 1993: 3 trials (Not applicable 1, Phase 3 2) 1994: 2 trials (Observational 1, Phase 3 1) 1995: 2 trials (Observational 1, Not applicable 1) 1996: 2 trials (Observational 1, Phase 3 1) 1997: 6 trials (Observational 2, Not applicable 2, Phase 3 2) 1998: 2 trials (Not applicable 1, Phase 2 1) 1999: 9 trials (Observational 1, Not applicable 2, Phase 4 1, Phase 3 2, Phase 2/3 1, Phase 2 2) 2000: 10 trials (Observational 4, Not applicable 1, Phase 3 4, Phase 1 1) 2001: 9 trials (Observational 1, Not applicable 1, Phase 3 7) 2002: 13 trials (Observational 4, Not applicable 1, Phase 4 5, Phase 3 1, Phase 2 2) 2003: 24 trials (Observational 5, Not applicable 2, Phase 4 6, Phase 3 8, Phase 2 3) 2004: 22 trials (Observational 8, Not applicable 4, Phase 4 5, Phase 3 4, Phase 2 1) 2005: 53 trials (Observational 10, Not applicable 12, Phase 4 14, Phase 3 14, Phase 2/3 1, Phase 2 2) 2006: 72 trials (Observational 22, Not applicable 14, Phase 4 15, Phase 3 11, Phase 2 6, Phase 1/2 2, Phase 1 2) 2007: 84 trials (Observational 23, Not applicable 13, Phase 4 21, Phase 3 11, Phase 2 10, Phase 1/2 1, Phase 1 5) 2008: 89 trials (Observational 30, Not applicable 13, Phase 4 19, Phase 3 9, Phase 2/3 4, Phase 2 8, Phase 1/2 3, Phase 1 3) 2009: 92 trials (Observational 22, Not applicable 14, Phase 4 26, Phase 3 8, Phase 2/3 3, Phase 2 13, Phase 1/2 4, Phase 1 2) 2010: 94 trials (Observational 19, Not applicable 25, Phase 4 18, Phase 3 14, Phase 2/3 2, Phase 2 10, Phase 1/2 4, Phase 1 2) 2011: 126 trials (Observational 32, Not applicable 37, Phase 4 21, Phase 3 16, Phase 2 14, Phase 1/2 2, Phase 1 4) 2012: 81 trials (Observational 20, Not applicable 26, Phase 4 14, Phase 3 7, Phase 2 7, Phase 1/2 4, Phase 1 3) 2013: 99 trials (Observational 29, Not applicable 29, Phase 4 19, Phase 3 6, Phase 2 9, Phase 1/2 2, Phase 1 5) 2014: 97 trials (Observational 21, Not applicable 33, Phase 4 8, Phase 3 11, Phase 2/3 1, Phase 2 14, Phase 1/2 4, Phase 1 5) 2015: 72 trials (Observational 16, Not applicable 28, Phase 4 6, Phase 3 9, Phase 2/3 1, Phase 2 7, Phase 1 5) 2016: 85 trials (Observational 23, Not applicable 31, Phase 4 8, Phase 3 10, Phase 2 6, Phase 1/2 2, Phase 1 5) 2017: 90 trials (Observational 26, Not applicable 42, Phase 4 6, Phase 3 5, Phase 2/3 1, Phase 2 5, Phase 1/2 1, Phase 1 4) 2018: 112 trials (Observational 26, Not applicable 60, Phase 4 4, Phase 3 11, Phase 2/3 1, Phase 2 3, Phase 1/2 2, Phase 1 5) 2019: 85 trials (Observational 25, Not applicable 30, Phase 4 8, Phase 3 10, Phase 2 3, Phase 1/2 3, Phase 1 6) 2020: 96 trials (Observational 24, Not applicable 52, Phase 4 8, Phase 3 4, Phase 2 4, Phase 1/2 2, Phase 1 2) 2021: 107 trials (Other 1, Observational 26, Not applicable 52, Phase 4 7, Phase 3 9, Phase 2 8, Phase 1/2 1, Phase 1 3) 2022: 101 trials (Observational 26, Not applicable 56, Phase 4 4, Phase 3 6, Phase 2 3, Phase 1/2 2, Phase 1 4) 2023: 92 trials (Observational 19, Not applicable 56, Phase 4 5, Phase 3 2, Phase 2/3 2, Phase 2 4, Phase 1/2 2, Phase 1 2) 2024: 78 trials (Observational 25, Not applicable 29, Phase 4 7, Phase 3 5, Phase 2 5, Phase 1 7) 2025: 104 trials (Observational 31, Not applicable 49, Phase 4 7, Phase 3 5, Phase 2/3 1, Phase 2 6, Phase 1/2 3, Phase 1 2)

Trials registered with a start date in each year, 1990 onward, stacked by phase (complete years only; the current partial year is in the table's notes). The table below lists the same counts, most recent years first.

Trials started per year
Year Trials started
2026 (partial year) 98
2025 104
2024 78
2023 92
2022 101
2021 107
2020 96
2019 85
2018 112
2017 90

Showing 10 of 35 earlier years.

Start your 14-day trial Email me all 35 earlier years as a PDF

Forecast of the full-year count, planned starts included, not rows of this table: about 120 trials starting in 2026 and about 100 in 2027, the average of the 24 months through September, counted as registered and carried forward, with about 0.7 times the starts already registered for the rest of 2026 added. The rows of this table count trials registered so far with a start date in the year, planned starts included; the forecast looks ahead to the count for the whole year, so it is not the same measure. In backtests on conditions of this size, forecasts made part-way through the year were typically off by about 15 percent and ran about 1 percent high against the count later registered; forecasts made before the year began were off by about 26 percent and ran about 20 percent low against the count later registered. The part-way figures are from forecasts that used a multiple fitted only on earlier years. These figures rest on a few years of history (target years from 2018 to 2025, varying by figure), place each condition as it is mapped today rather than as it was then, and score against a count for the newest year that was still being revised. Only condition series were scored.

Prediction, not a registry value: median of 34 months from start to primary completion across 158 trials still running at the 2026-10-09 snapshot; registered median of 16 months across 1,385 trials with a primary completion typed Actual. Source: ClinicalTrials.gov / AACT (CTTI), public domain.

What phase are Ocular Hypertension trials in? (10)

Shown in this order: phase order.

Show the trials by phase as a table
Trials by phase
Phase Trials
Phase 1 83
Phase 1/2 47
Phase 2 162
Phase 2/3 19
Phase 3 228
Phase 4 280
Not applicable 774
Observational 550
Expanded access 2
Unknown 1

How many Ocular Hypertension trials are recruiting? (10)

Shown in this order: the order a trial moves through, from not yet recruiting to unknown.

Trials by recruitment status
Status Trials
Not yet recruiting 58
Recruiting 184
Enrolling by invitation 17
Active, not recruiting 60
Completed 1,265

Showing 5 of 10 statuses.

Start your 14-day trial Email me all 10 statuses as a PDF

Status as registered on ClinicalTrials.gov. Each trial is counted once.

Which lead sponsors run the most Ocular Hypertension trials? (6)

Shown in this order: most trials first. Lead sponsors the registry classes as industry, NIH, US federal, other government or network. A hospital or university the registry files as government can appear here. Sponsors it classes as academic or other are shown on the full page, because that class cannot separate an institution from a named investigator.

Lead sponsors
Sponsor Trials
Alcon Research 135
Allergan 90
Glaukos Corporation 48
Pfizer's Upjohn has merged with Mylan to form Viatris Inc. 27
Aerie Pharmaceuticals 25

Showing 5 of 6 sponsors.

Start your 14-day trial Email me all 6 sponsors as a PDF

Which drugs are being tested for Ocular Hypertension? (3)

Shown in this order: most trials first. One row per drug, matched to a single molecule under all its names, ranked by number of trials.

Drugs tested
Drug Trials
Timolol hemihydrate 28
Bimatoprost 18
Brimonidine 15

Interventions as named in the registry (12)

Shown in this order: most trials first.

Interventions as named in the registry
Drug Trials
Apo-Latanoprost 93
travoprost 0.003% 45
Latanoprost 0.005% 19
Cataract surgery 17
Latanoprost 0.005% Ophthalmic Solution 16

Showing 5 of 12 interventions.

Start your 14-day trial Email me all 12 interventions as a PDF

These are the names sponsors entered on ClinicalTrials.gov that we have not matched to a single molecule. Some are drugs under a brand or code name; others are procedures, doses or arm labels.

Which serious adverse events do Ocular Hypertension trials report? (10)

Shown in this order: most subjects affected first. Subjects affected summed across trials, a cross-trial signal, not a rate.

Serious adverse events in this condition's trials
Adverse event Subjects affected Trials
Death 40 17
Pneumonia 40 25
Corneal endothelial cell loss 34 4
Intraocular pressure increased 30 11
Hypotony 25 1

Showing 5 of 10 adverse events.

Start your 14-day trial Email me all 10 adverse events as a PDF

Which publications cover Ocular Hypertension? (426)

Shown in this order: major-topic papers first, then newest, then most linked to trials.

Publications
Publication Journal Year Major topic
Phase 3, Randomized, Comparison Study of Intracameral Bimatoprost Implant 10 µg and Selective Laser Trabeculoplasty. American journal of ophthalmology 2025 Yes
Prospective 18-Month Study of Bimatoprost Intracameral Implant in Patients with Open-Angle Glaucoma or Ocular Hypertension in US Clinical Practice. Drugs 2025 Yes
Selective Laser Trabeculoplasty After Medical Treatment for Glaucoma or Ocular Hypertension. JAMA ophthalmology 2025 Yes
Safety and Longevity of Intraocular Pressure Control After Bimatoprost Implant Administration: Interim Analysis of a Phase 3b Clinical Trial (TRITON). Drugs 2025 Yes
Sepetaprost 0.002% Noninferiority vs. Timolol 0.5% in Patients with Primary Open-Angle Glaucoma or Ocular Hypertension: ANGEL-2. Ophthalmology. Glaucoma 2025 Yes

Showing 5 of 426 publications.

Start your 14-day trial Email me the first 50 publications as a PDF

Sub-conditions in MeSH (1)

MeSH descendants one level down with at least one trial, most trials first.

Not on this page

Not measured: delivery record.

Checked, with nothing recorded for this condition: prevalence and rare-disease identity.

Browse all condition evidence pages